Analysis of MGMT methylation with the therascreen® MGMT Pyro® Kit (Qiagen). A method verification - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Annales de Biologie Clinique Année : 2015

Analysis of MGMT methylation with the therascreen® MGMT Pyro® Kit (Qiagen). A method verification

Résumé

Promoter methylation of the MGMT gene, encoding the enzyme O6-methylguanine-ubiquitous methyltransferase, is a theranostic good prognosis marker of glioblastomas treated with alkylating chemotherapy (temozolomide, Temodal(®)). Among the methylation analysis techniques, pyrosequencing is a reproducible and sensitive quantitative method. As part of the accreditation of the hospital platform of molecular genetics of cancer, Besançon, our objective was to verify the performance of the pyrosequencing commercial kit therascreen(®) MGMT Pyro(®) (Qiagen) in terms of repeatability, reproducibility, limit of blank (LOB), limit of detection (LOD), linearity and contamination by the guide SH GTA 04 delivered by the Cofrac. The repeatability tests show an average methylation of 3.22% [standard deviation (SD) = 0.41, coefficient of variation (CV) = 12.75%] for the unmethylated control and 70.16% (SD = 2.20, CV = 3.14%) for the methylated control. Reproducibility demontrates an average methylation of 1.39% (SD = 0.25, CV = 18.25%) for the unmethylated control and of 94.03% (SD = 2.56, CV = 2.73%) for the methylated control. The percentages of LOB and LOD are respectively 3.43% and 6.22% methylation. The regression coefficient of 0,983 confirms the linearity of the assay from 0% to 100% methylation. No contamination has been observed. Over 40% of glioblastomas studied in 2013 in our laboratory have shown a methylated MGMT gene. Our results confirms that the theraScreen(®) MGMT Pyro(®) kit (Qiagen) is performant in compliance with the quality requirements of the NF EN ISO 15189 for the routine analysis of methylation status of MGMT in glioblastomas.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-03172479 , version 1 (17-03-2021)

Identifiants

Citer

Alexandra Luquain, Sandrine Magnin, David Guenat, Jean-Luc Pretet, Gabriel Viennet, et al.. Analysis of MGMT methylation with the therascreen® MGMT Pyro® Kit (Qiagen). A method verification. Annales de Biologie Clinique, 2015, 73 (6), pp.665-670. ⟨10.1684/abc.2015.1099⟩. ⟨hal-03172479⟩

Collections

UNIV-FCOMTE
31 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More